The Health Ministry will recommend the use of the drugs for COVID-19 based on monoclonal antibodies, namely kasirivimab and imdevimab from the Regeneron firm and bamlanivimab from the Eli Lilly firm, it said in a press release today. These drugs are suitable for people with a high risk of severe symptoms of the infection disease, for example patients after transplants. The target groups are yet to be defined.